# Resource Summary Report

Generated by NIF on Jul 29, 2026

## Alexa Fluor(R) 700 anti-human CD3

RRID:AB_2563407
Type: Antibody

### Proper Citation

BioLegend Cat# 317339, RRID:AB_2563407

### Antibody Information

**URL:** http://antibodyregistry.org/AB_2563407

**Proper Citation:** BioLegend Cat# 317339, RRID:AB_2563407

**Target Antigen:** CD3

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** Alexa Fluor(R) 700 anti-human CD3

**Description:** This monoclonal targets CD3

**Target Organism:** human

**Clone ID:** Clone OKT3

**Antibody ID:** AB_2563407

**Vendor:** BioLegend

**Catalog Number:** 317339

**Alternative Catalog Numbers:** 317340

**Record Creation Time:** 20250819T204645+0000

**Record Last Update:** 20250819T204728+0000

### Ratings and Alerts

No rating or validation information has been found for Alexa Fluor(R) 700 anti-human CD3.

No alerts have been found for Alexa Fluor(R) 700 anti-human CD3.

## Data and Source Information

**Source:** Antibody Registry

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at NIF .


Porazzi P, et al. (2025) EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer cell, 43(3), 537.

Wang W, et al. (2025) BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanoma. Cell reports. Medicine, 6(3), 101995.

Martínez-Balboa Y, et al. (2025) Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine. iScience, 28(8), 113167.

Shen C, et al. (2025) ALKBH1 drives tumorigenesis and drug resistance via tRNA decoding reprogramming and codon-biased translation. Cancer discovery.

Montalban-Bravo G, et al. (2024) Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. Cell reports. Medicine, 5(6), 101585.

Zhao Y, et al. (2023) cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8+ T cell function and anti-tumor immunity. Immunity.